Video

Safety of Cemiplimab for Basal Cell Carcinoma

Author(s):

Jennifer L. Atlas, MD,Shahab Babakoohi, MD

Experts review the safety and toxicity data of anti-PD-1 antibody agent cemiplimab for basal cell carcinoma treatment.

Related Videos
Michael A. Postow, MD
Matthew P. Deek, MD
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Related Content
ReisMedia - stock.adobe.com
December 4th 2024

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Douglas B. Johnson, MD, MSCI
November 22nd 2024

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors